• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Zenas BioPharma Inc.

    4/1/25 9:47:58 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZBIO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Zenas BioPharma, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001

    (Title of Class of Securities)


    98937L105

    (CUSIP Number)


    03/25/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    98937L105


    1Names of Reporting Persons

    Novo Holdings A/S
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DENMARK
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,214,967.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,214,967.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,214,967.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.3 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Zenas BioPharma, Inc.
    (b)Address of issuer's principal executive offices:

    852 Winter Street, Suite 250, Waltham, Massachusetts 02451
    Item 2. 
    (a)Name of person filing:

    Novo Holdings A/S, a Danish corporation, is an investment firm focused on life sciences and finance that is wholly owned by Novo Nordisk Foundation (the "Foundation"), a Danish commercial foundation. Novo Holdings A/S is the holding company in the group of Novo companies, currently comprised of Novo Nordisk A/S and Novozymes A/S (also known as Novonesis A/S), and is responsible for managing the Foundation's assets, including its financial assets. Based on the governance structure of Novo Holdings A/S and the Foundation, the Foundation is not deemed to have any beneficial ownership of the securities of the Issuer held by Novo Holdings A/S.
    (b)Address or principal business office or, if none, residence:

    Tuborg Havnevej 19 2900 Hellerup, Denmark
    (c)Citizenship:

    Denmark
    (d)Title of class of securities:

    Common Stock, par value $0.0001
    (e)CUSIP No.:

    98937L105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    2,214,967
    (b)Percent of class:

    5.3  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    2,214,967

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    2,214,967

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Novo Holdings A/S
     
    Signature:/s/ Barbara Fiorini
    Name/Title:General Counsel, Finance & Operation
    Date:04/01/2025
    Get the next $ZBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZBIO

    DatePrice TargetRatingAnalyst
    3/20/2025$35.00Outperform
    Wedbush
    2/4/2025$19.00Outperform
    Wolfe Research
    12/16/2024$30.00Buy
    H.C. Wainwright
    11/5/2024$34.00Buy
    Rodman & Renshaw
    10/8/2024$45.00Buy
    Guggenheim
    10/8/2024$40.00Overweight
    Morgan Stanley
    10/8/2024$35.00Buy
    Jefferies
    10/8/2024$27.00Buy
    Citigroup
    More analyst ratings

    $ZBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zenas BioPharma to Present at the Jefferies Global Healthcare Conference

      WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced management's presentation at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 1:25 p.m. ET. A live webcast and archived replay of the Company's presentation can be accessed under "Events and Presentations" in the Investor & Media Relations section of the Zenas BioPharma website. About Zenas BioPharma, Inc.Zenas is a clinical-stage global biopharmaceutical company committed to becomin

      5/29/25 7:05:00 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates

      - Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - - Phase 2 MoonStone trial in Relapsing Multiple Sclerosis enrollment concluding; topline results expected early in the fourth quarter 2025 - - Enrollment of Phase 2 SunStone trial in Systemic Lupus Erythematosus expected to be completed by year-end 2025; topline results expected mid-2026 - - Strengthened leadership team with appointments of Lisa von Moltke, M.D., Head of Research and Development and Chief Medical Officer, and Haley Laken, Ph.D., Chief Scientific Officer - - Cash, cash equivalents and investments of $314.2 million as of March 31, 2025, expected to provi

      5/15/25 7:05:00 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on April 15, 2025 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors (the "Committee") granted non-qualified stock options to two newly hired officers of the Company, each as an inducement material to each officer's entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4). The Committee granted a non-qualified stock option to purchase

      4/17/25 4:20:32 PM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Zenas BioPharma Inc.

      SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)

      11/12/24 10:40:28 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Zenas BioPharma Inc.

      SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)

      10/21/24 4:18:16 PM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Zenas BioPharma Inc.

      SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)

      9/25/24 6:00:11 PM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZBIO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Zenas BioPharma Inc.

      10-Q - Zenas BioPharma, Inc. (0001953926) (Filer)

      5/15/25 7:25:28 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zenas BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Zenas BioPharma, Inc. (0001953926) (Filer)

      5/15/25 7:14:53 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Zenas BioPharma Inc.

      SCHEDULE 13G/A - Zenas BioPharma, Inc. (0001953926) (Subject)

      5/12/25 10:20:43 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ZBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ZBIO
    Leadership Updates

    Live Leadership Updates

    See more

    $ZBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amendment: Director Xiao Ting bought $77,600 worth of shares (10,000 units at $7.76) (SEC Form 4)

      4/A - Zenas BioPharma, Inc. (0001953926) (Issuer)

      4/28/25 7:07:52 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Moulder Leon O Jr bought $166,750 worth of shares (25,000 units at $6.67), increasing direct ownership by 10% to 266,155 units (SEC Form 4)

      4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

      2/19/25 4:01:11 PM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Xiao Ting bought $77,600 worth of shares (10,000 units at $7.76), increasing direct ownership by 27% to 47,000 units (SEC Form 4)

      4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

      2/11/25 4:20:30 PM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Xiao Ting bought $77,600 worth of shares (10,000 units at $7.76) (SEC Form 4)

      4/A - Zenas BioPharma, Inc. (0001953926) (Issuer)

      4/28/25 7:07:52 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Von Moltke Lisa

      4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

      4/17/25 4:01:17 PM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Von Moltke Lisa

      3 - Zenas BioPharma, Inc. (0001953926) (Issuer)

      3/21/25 4:01:08 PM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer

      WALTHAM, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Haley Laken, Ph.D., as Chief Scientific Officer (CSO). Dr. Laken brings significant scientific insight and leadership experience in research, development operations, R&D strategy and business development. "Haley is an accomplished R&D leader with expertise in translational research, drug development and operations. She has advanced programs through the clinic leading to regulatory approv

      4/7/25 7:05:00 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer

      –Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies– WALTHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Lisa von Moltke, M.D., as its Head of Research and Development and Chief Medical Officer (CMO). Dr. von Moltke brings over 30 years of U.S. and international drug development experience s

      3/17/25 7:05:00 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Zenas Biopharma with a new price target

      Wedbush initiated coverage of Zenas Biopharma with a rating of Outperform and set a new price target of $35.00

      3/20/25 8:00:59 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Zenas Biopharma with a new price target

      Wolfe Research initiated coverage of Zenas Biopharma with a rating of Outperform and set a new price target of $19.00

      2/4/25 7:13:29 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Zenas Biopharma with a new price target

      H.C. Wainwright initiated coverage of Zenas Biopharma with a rating of Buy and set a new price target of $30.00

      12/16/24 6:47:20 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care